iBio, Inc. develops AI-driven precision antibody therapies for cardiometabolic, obesity and cardiopulmonary diseases. Company news commonly covers pipeline updates for IBIO-600, a long-acting anti-myostatin monoclonal antibody, and IBIO-610, an Activin E antibody candidate, along with preclinical body-composition data and regulatory clearances tied to early clinical development.
Recurring updates also include iBio's antibody-discovery approach, including computational biology and epitope-steering, as well as financial results, capital financing, investor-conference presentations and board or committee changes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.